$TriSalus Life Sciences (TLSI.US)$ TriSalus宣布《血管和介入放射学杂志》发表了数据,证明了使用PEDD™方法通过TriNav®输注系统改善了对固体肿瘤的玻璃微球的治疗递送 TriSalus Life Sciences(纳斯达克:TLSI)宣布在《血管介入和放射学杂志》发表研究,展示了利用他们的压力驱动药物输送系统(PEDD)方法将玻璃微球更好地输送到肝脏肿瘤。
$TriSalus Life Sciences (TLSI.US)$Late-Breaking Phase 1 Liver Metastasis Data from TriSalus Presented at SITC 2023 Supports Development of Innovative Immuno-oncology Approach for Liver and Pancreas Indications Via BusinessWire TLSI Share – New data from PERIO-01 clinical trial indicates PEDD™ method resulted in modulation of the tumor microenvironment by enabling performance of the TLR9 agonist, SD-101, in metastatic uveal melanoma, consistent with an earlier ...
TriSalus Life Sciences股票讨论区
TriSalus宣布《血管和介入放射学杂志》发表了数据,证明了使用PEDD™方法通过TriNav®输注系统改善了对固体肿瘤的玻璃微球的治疗递送
TriSalus Life Sciences(纳斯达克:TLSI)宣布在《血管介入和放射学杂志》发表研究,展示了利用他们的压力驱动药物输送系统(PEDD)方法将玻璃微球更好地输送到肝脏肿瘤。
暂无评论